Characterization of absorbable collagen sponges as rhBMP-2 carriers.
For clinical use recombinant human bone morphogenetic protein (rhBMP-2) is soaked onto an absorbable collagen sponge (ACS) for bone regeneration. Therefore, loss of rhBMP-2 upon mechanical handling during implantation and a potential effect of the carrier on in vivo retention is of interest. The interactions between drug and carrier were looked at from the application mode and the amount of protein which can be mechanically expressed from the combination was investigated. The results indicated that rhBMP-2 binds to the collagen system. The most hydrophilic double extended homodimer showed the least binding affinity to ACS. By extending the waiting time between soaking and implantation, protein incorporation could be increased. In addition, the amount of rhBMP-2 which could be expressed was reduced by heavier ACS material and allowed for a shorter waiting period, especially at lower rhBMP-2 concentration. Crosslinking of ACS with formaldehyde led to reduced binding of rhBMP-2 to collagen either by direct hindrance of binding or reduction in swelling and number of binding sites available. Higher product pH or anion concentration enabled to increase rhBMP-2 incorporation but was limited by the potential precipitation of rhBMP-2. Despite a variety of chemical changes of ACS by ethylene oxide sterilization incorporation was not changed significantly. The in vivo release kinetics of 125I-rhBMP-2 from the collagen sponge were studied using a rat ectopic implant model. The ACS/rhBMP-2 systems tested demonstrated small, but significant differences in the in vivo retention of rhBMP-2. Consequently, it is important to have as little variability in pH, anion concentration, crosslinking and ACS mass as possible to achieve consistent or maximum binding and to avoid rhBMP-2 precipitation. Furthermore, these characteristics can be important for other in vivo applications.
Friess
W
W
Department of Pharmaceutical Technology, University of Erlangen, Cauerstrasse 4, 91058, Erlangen, Germany.
Uludag
H
H
Foskett
S
S
Biron
R
R
Sargeant
C
C
D020341:Absorbable Implants; D000818:Animals; D000838:Anions; D001672:Biocompatible Materials / Q000008:administration & dosage* / Q000737:chemistry*; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*; D016466:CHO Cells / Q000378:metabolism; D003094:Collagen / Q000008:administration & dosage* / Q000737:chemistry*; D006224:Cricetinae; D003432:Cross-Linking Reagents; D004337:Drug Carriers; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007457:Iodine Radioisotopes; D020033:Protein Isoforms; D051381:Rats; D020318:Rats, Long-Evans; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*; D013242:Sterilization; D016212:Transforming Growth Factor beta
D000838:Anions; C525718:BMP2 protein, human; D001672:Biocompatible Materials; C525720:Bmp2 protein, rat; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D003432:Cross-Linking Reagents; D004337:Drug Carriers; D007457:Iodine Radioisotopes; D020033:Protein Isoforms; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2; D003094:Collagen